Trial · NCT06367283
Metformin Treatment of Patients with Hand Osteoarthritis
NCT06367283, Phase 3, Recruiting, Marius Henriksen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin Treatment of Patients with Hand Osteoarthritis. Trials, record NCT06367283. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06367283
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin Treatment of Patients with Hand Osteoarthritis
- NCT number
- NCT06367283
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Marius Henriksen
- Conditions
- Hand Osteoarthritis
- Interventions
- Metformin, Placebo
- First posted
- 2024-04-16
- Last updated
- 2025-02-27
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Finger pain | Week 16 | Change from baseline in Visual Analogue Scale (VAS) finger joint pain of the target hand after 16 weeks of treatment |
| Secondary | Function | Week 16 | Change from baseline after 16 weeks of treatment in physical function assessed by Australian/Canadian Osteoarthritis Hand Index (AUSCAN) physical function subscale |
| Secondary | Thumb base pain | Week 16 | Change from baseline after 16 weeks of treatment in Visual Analogue Scale thumb base pain of the target hand |
| Secondary | Hand pain | Week 16 | Change from baseline after 16 weeks of treatment in pain of both hands assessed by Australian/Canadian Osteoarthritis Hand Index hand pain subscale |
| Secondary | Physician tender joint count | Week 16 | Change from baseline after 16 weeks of treatment in joint activity of the target hand assessed by physician tender joint count |
| Secondary | Patient global assessment | Week 16 | Change from baseline after 16 weeks of treatment in Visual Analogue Scale patient global assessment |
| Secondary | Quality of life assessed by the European Quality of life - 5 dimensions (EQ-5D) scale | Week 16 | Change from baseline after 16 weeks of treatment in quality of life assessed by the European Quality of life - 5 dimensions scale |
| Secondary | Hand strength | Week 16 | Change from baseline after 16 weeks of treatment in hand strength of the target hand assessed by a grip dynamometer |
| Secondary | Number of treatment responders | Week 16 | Responders will be identified according to OMERACT-OARSI criteria, defined as (1) improvement in finger pain (primary outcome) or function (secondary outcome) ≥50% and an absolute change ≥20 mm; or (2) improvement of ≥20% with an absolute change ≥10 mm in at least two of the following three: finger pain (primary outcome), function (secondary outcome), and patient global assessment (secondary outcome). |
| Other | Stiffness of both hands | Week 16 | Change in stiffness of both hands measured on the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) stiffness subscale |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40139705 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06367283
GET https://conductscience.org/api/trials/v1/NCT06367283/registered?page=2